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a  b  s  t  r  a  c  t
Infection  of  humans  and  livestock  with  parasitic  nematodes  can  have  devastating  effects  on  health  and
production,  affecting  food  security  in both  developed  and  developing  regions.  Despite  decades  of research,
the  development  of  recombinant  sub-unit  vaccines  against  these  pathogens  has  been  largely  unsuccess-
ful.  We  have  developed  a strategy  to identify  protective  antigens  from  Teladorsagia  circumcincta, the
major  pathogen  causing  parasitic  gastroenteritis  in  small  ruminants  in  temperate  regions,  by studying
IgA  responses  directed  at proteins  speciﬁc  to post-infective  larvae.  Antigens  were  also  selected  on the
basis  of their  potential  immunomodulatory  role  at the  host/parasite  interface.  Recombinant  versions  of
eight molecules  identiﬁed  by immunoproteomics,  homology  with  vaccine  candidates  in  other  nematodes
and/or  with  potential  immunoregulatory  activities,  were  therefore  administered  to  sheep  in  a  single
vaccine  formulation.  The  vaccine  was  administered  three  times  with  Quil  A  adjuvant  and  the  animals
subsequently  subjected  to a repeated  challenge  infection  designed  to  mimic  ﬁeld  conditions.  Levels  of
protection  in  the vaccinates  were  compared  to  those  obtained  in  sheep  administered  with  Quil A  alone.
The trial  was  performed  on two  occasions.  In both  trials,  vaccinates  had  signiﬁcantly  lower  mean  fecal
worm  egg  counts  (FWECs)  over  the  sampling  period,  with  a  mean  reduction  in egg output  of  70% (Trial
1) and  58%  (Trial 2).  During  the  period  of peak  worm  egg  shedding,  vaccinates  shed  92%  and  73% fewer
eggs  than  did controls  in  Trials  1  and  2, respectively.  At  post mortem,  vaccinates  had  75% (Trial  1)  and
56%  (Trial  2) lower  adult  nematode  burdens  than  the  controls.  These  levels  of  protection  are  the  high-
est  observed  in any  system  using  a nematode  recombinant  sub-unit  vaccine  in  the  deﬁnitive  ruminant
host  and indicate  that  control  of  parasitic  helminths  via  vaccination  with  recombinant  subunit  vaccine
cocktails  is  indeed  an  alternative  option  in the face  of  multi-drug  resistance.
e Aut© 2013 Th
. Introduction
Infection of livestock and humans with parasitic nematodes
as devastating effects on health and production, affecting food
ecurity worldwide [1,2]. Despite decades of research, the devel-
pment of recombinant vaccines against these pathogens has been
nsuccessful [3,4]. The primary cause of parasitic gastroenteritis
PGE) in small ruminants in temperate regions worldwide is the
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nematode Teladorsagia circumcincta. Infection is acquired via inges-
tion of third stage larvae (L3) from pasture. Thereafter, immature
(xL3 and L4) and adult worms reside in the host’s abomasum caus-
ing substantial production losses [5]. Currently, T. circumcincta is
controlled using anthelmintics; however, multi-drug resistance is
widespread [6,7] and development of a vaccine is now a priority.
Protective immunity against T. circumcincta develops after pro-
longed continual exposure [8] and the degree of immunity acquired
depends on the level of parasite challenge, animal age and geno-
type [9]. Immunity is associated with decreased establishment
and development rate of nematode larvae in the abomasal glands
and reduced egg output from adults [8,10–13]. The mechanisms
Open access under CC BY-NC-ND license. responsible for these effects are complex: immediate hypersen-
sitivity reactions, cellular effectors and humoral responses have
all been indicated [12,14–22]. The successful adoptive transfer of
immunity, using gastric lymph of previously-infected lambs, to
C-ND license. 
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Table 1
Recombinant proteins used in Teladorsagia circumcincta vaccine trial.
Name Accession number Functiona Expression system/solubility Reference
Tci-SAA-1 CAQ43040 L3-enriched surface associated antigen pET22b(+) E. coli BL21 (DE3)-RIL Soluble [26]
Tci-MIF-1 CBI68362 L3-enriched macrophage migration inhibitory factor pET22b(+) E. coli BL21 (DE3)-RIL Soluble [29]
Tci-ASP-1 CBJ15404 L4-enriched activation-associated secretory protein pET SUMO E. coli BL21 (DE3)-RIL Soluble [31]
Tci-TGH-2 ACR27078 Transforming growth protein 2-like protein pET SUMO E. coli BL21 (DE3)-RIL Soluble [28]
Tci-CF-1 ABA01328b L4-enriched Secreted cathepsin F pPICZC Pichia pastoris X33 strain Soluble [23]
Tci-ES20 HF677587 Excretory/secretory (ES) protein pPICZC Pichia pastoris X33 strain Soluble [21]
Tci-MEP-1 HF677586 Astacin-like ES metalloproteinase pET SUMO E. coli BL21 (DE3)-RIL Insoluble [21]
Tci-APY-1 CBW38507 L4-enriched ES calcium-activated apyrase pSUMO E. coli BL21 (DE3)-RIL Soluble [30]
a Putative or inferred function.
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bb Tci-CF-1 is highly polymorphic, the clone used for vaccine production had the
mino  acid in the published sequence is in italics, that in the vaccine isoform sequen
44 ⇒ T44, N101 ⇒ D101, T129 ⇒ A129, R137 ⇒ Q137, R305 ⇒ K305, L306 ⇒ P306, S307 ⇒ Y307.
elminth-free monozygotic twins highlighted the importance of
ocal immune responses in protection against re-infection [12] and
arval antigen-speciﬁc IgA in gastric secretions has been implicated
s playing a crucial role [12,14–16,19,21].
We developed a tripartite approach to identifying antigens for
 T. circumcincta vaccine. First, we selected proteins [cathepsin F-1
Tci-CF-1), astacin-like metalloproteinase-1 (Tci-MEP-1), a 20 kDa
rotein of unknown function (Tci-ES20) and activation-associated
ecretory protein-1 (Tci-ASP-1)] [21,23,31] by examining larval
ntigens that are targets of IgA in immune sheep [21,23], focus-
ng on proteins excreted or secreted during the critical phase of
orm growth and development [24]. We  also selected Tci-SAA-1,
n immunogenic homologue of a protective antigen from canine
ookworm, Ancylostoma caninum (Ac-SAA-1 [25,26]) by bioinfor-
atic analysis of T. circumcincta transcripts [26,27]. Finally, we
dentiﬁed potentially immunosuppressive molecules released by
he larvae [macrophage migration inhibitory factor-1 (Tci-MIF-1),
alcium-dependent apyrase-1 (Tci-APY-1) and a TGF homologue
Tci-TGH-2)] [28–30]. Here, we combined these antigens into a
accine which could, in theory, nullify the immunomodulatory
unctions of parasite-derived molecules and concurrently allow
nhanced immune responses against the immunostimulatory com-
onents. We  tested the vaccine in two independent trials in which
heep were administered a sustained larval challenge after vacci-
ation.
. Materials and methods
.1. Recombinant protein production
Eight recombinant proteins (Table 1) were produced. Produc-
ion of recombinant Tci-SAA-1, Tci-MIF-1 and Tci-APY-1 has been
escribed previously [26,29,30]. Tci-MEP-1 cDNA was ampliﬁed
rom T. circumcincta RNA (L4, prepared as in [27]) using the
MARTTM RACE kit (Clontech) and sub-cloned into pET SUMO (Invi-
rogen) (omitting bases 1–48 encoding the signal peptide). The
oding sequences (CDS) of Tci-tgh-2 and Tci-asp-1 (omitting signal
eptide bases [31]) were each sub-cloned into pET SUMO (Invi-
rogen). Expression of recombinant proteins (Tci-SAA-1, Tci-MIF-1,
ci-APY-1, Tci-MEP-1, Tci-TGH-2 and Tci-ASP-1) in Escherichia
oli BL21-CodonPlus® (DE3)-RIL competent cells (Stratagene) was
nduced using 1 mM isopropyl -d-1-thiogalactopyranoside (IPTG).
he CDS of Tci-cf-1, (omitting signal peptide bases 1–42) and the
DS of Tci-ES20 (PCR-ampliﬁed from a T. circumcincta L4 SMARTTM
DNA library), were each sub-cloned into pPICZC  (Invitrogen) and
sed to transform P. pastoris [X-33 (Mut+) (Invitrogen)]. Tci-CF-1
nd Tci-ES20 protein expression was induced with 0.5% methanol
32]. Soluble recombinant proteins were puriﬁed from cell lysates
E. coli) or culture supernatant (P. pastoris) using HisTrapTM HP
olumns (GE Healthcare), then dialysed against 20 mM phosphate
uffer, 0.5 M NaCl, pH 7.6. Insoluble recombinant Tci-MEP-1 waswing amino acid substitutions compared to published sequence. In each case the
 normal font and the amino acid position in the published sequence is in subscript:
puriﬁed via nickel column afﬁnity chromatography in the presence
of 8 M urea, then dialysed against 2 M urea in 20 mM phosphate
buffer, 0.5 M NaCl, pH 7.6. Protein concentrations were determined
using the Pierce BCATM (bicinchoninic acid) assay (Thermo Scien-
tiﬁc) with bovine serum albumin (BSA) standards and the integrity
of each recombinant protein monitored via SDS-PAGE.
2.2. Immunization experiments
2.2.1. Trial 1
Fourteen Texel crossbred lambs, 204–206 days old, reared under
conditions to exclude helminth infection (conﬁrmed by fecal worm
egg counts (FWECs), [33]), were housed in two groups of 7 animals
in separate pens. Sheep in Group 1 were injected subcutaneously
with 400 g recombinant protein mix  (incorporating 50 g each
of Tci-ASP-1; Tci-MIF-1; Tci-TGH-2; Tci-APY-1; Tci-SAA-1; Tci-CF-
1; Tci-ES20; Tci-MEP-1) plus 10 mg  Quil A (Brenntag Biosector).
PBS-soluble proteins were administered as a mixture in a sin-
gle injection with 5 mg  Quil A in PBS. Tci-MEP-1 was formulated
with 2 M urea in PBS plus 5 mg  Quil A. The preparations were
injected separately at two sites on the neck. Three immuniza-
tions were administered, 3 weeks apart. Sheep in Group 2 received
three immunizations with urea/PBS/10 mg  Quil A, at the same
time as Group 1. Following the ﬁnal immunization each sheep
was administered orally with 2000 T. circumcincta L3, three times
per week for 4 weeks. FWECs were performed three times per
week from 14 days after the start of the L3 challenge period
until the end of the experiment. Cumulative FWEC values were
estimated using the trapezoidal method for calculation [34]).
Abomasal nematode burdens were classiﬁed and enumerated fol-
lowing standard techniques [20,24,35]. Blood samples were taken
prior to each immunization and weekly from the third immuniza-
tion. Abomasal swab samples were collected at post-mortem [21]
to determine levels of antigen-speciﬁc IgA and IgG in abomasal
mucus.
2.2.2. Trial 2
Twenty-eight Texel crossbred lambs, 172–178 days old, were
raised as described for Trial 1 and housed in four groups of 7 ani-
mals. Groups 1 and 3 were immunized with recombinant protein
mix  as described for Trial 1. Sheep in Groups 2 and 4 received
immunizations with urea/PBS/Quil A, at the same time as Groups 1
and 3. At the ﬁnal immunization, oral L3 challenge commenced
in all Groups for 4 weeks. All biological samples were obtained
as described above. Sheep in Groups 1 and 2 were euthanized 7
weeks after the start of the infection period and those in Groups 3
and 4 were euthanized 4 weeks later. Trials were performed under
the regulations of a UK Home Ofﬁce Project Licence; experimental
design was  ratiﬁed by MRI’s Experiments and Ethics Committee.
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.3. Measurement of antibody responses
Recombinant antigen-speciﬁc IgG and IgA levels in serum and
bomasal mucus from each animal were assessed by ELISA as
escribed previously [31]. In addition, the binding of serum IgG
o native T. circumcincta antigens was also assessed as follows:
ative antigens (L4 ES products, prepared from ex vivo L4 nema-
odes maintained in culture for 48 h, as described in [21]) were used
o coat ELISA plates and antigen-speciﬁc IgG levels were assessed
n sera from all animals in Trial 1 and from four, randomly selected,
nimals from Groups 1 and 2 of Trial 2. Each sample was assayed
n triplicate. OD values were corrected against a reagent blank and
ll test plates had a positive and negative serum control to account
or plate to plate variation.
.4. Immunoblotting of nematode somatic extracts
Somatic extracts of T. circumcincta L3, L4 and adult worms [26],
long with L4 ES products, [21], were subjected to immunoblotting
o determine serum IgG and IgA binding to components of each
xtract, as described previously [26], using pools of sera from 7
mmunized (Group 3) and 7 control sheep (Group 4) collected on
he date of the third (ﬁnal) immunization before infection.
.5. Statistical analysis
For longitudinal FWEC analysis, a generalised additive mixed
odel (GAMM)  model on log(FWEC + 1) was speciﬁed (Gaussian
rror structure and identity link function, group as ﬁxed effect,
nimal effects as random). The model included separate smooth-
ng curves for the nonlinear relationship of the response with
ime by group, non-homogenous within-group variances were
llowed. A ﬁrst order autoregressive residual correlation structure
as incorporated. Antibody responses were modeled using linear
ixed models (LMMs) (group as ﬁxed effect, animal as random
ffect). For serum antibody data, repeated measures over time were
odeled by random intercept and slope LMMs,  including time and
ts interaction with group as ﬁxed effect. Heterogeneous within-
roup variances were allowed. Linear contrasts compared subsets
f responses in abomasal mucus.
In Trial 2, the 28 animals were housed in 4 separate groups of 7
nimals. No statistically signiﬁcant pen effects were found between
roups 1 and 3 or Groups 2 and 4, so Groups 1 and 3 were combined
nd Groups 2 and 4 were combined for data modeling. For analyses
f worm burden data, generalised linear models (GLMs) were used.
ata overdispersion was generally accounted for by specifying a
egative binomial error distribution. Where necessary, overdisper-
ion was incorporated using Poisson GLMs correcting the standard
rrors by specifying the mean and variance relationship.
Model selection was based on the Akaike’s information crite-
ion (AIC) and likelihood ratio tests (LRT); optimal mixed models
ere ﬁtted by residual maximum likelihood (REML). Comparisons
etween groups were made by evaluating marginal statistical sig-
iﬁcances of the associated ﬁxed effect by conditional t-tests.
ook’s distance with a 4/n  cut-off was used to support decisions
or outliers. Statistical signiﬁcance was assessed at the 5% level.
tatistical analyses were conducted using R version 2.13.
. Results
.1. FWEC analysisIn Trial 1, sheep in Groups 1 (immunized) and 2 (control, adju-
ant only) began to excrete T. circumcincta eggs in feces from 16
o 19 days after the start of challenge (Fig. 1A). At the ﬁnal time
oint, Group 1 sheep were producing a mean (±SEM) of 8.7 (±5.5)1 (2013) 4017– 4023 4019
eggs per gram (EPG) of feces, whereas sheep in Group 2 were pro-
ducing 107.6 (±50.8) EPG, representing a 92% reduction in mean
FWEC. GAMM analysis identiﬁed a statistically signiﬁcant effect of
immunization on mean FWEC over the timecourse of the experi-
ment (P < 0.001); mean cumulative FWECs were 595 (±316) EPG in
Group 1 and 1975 (±532) EPG in Group 2, representing an overall
reduction of 70% in the immunized versus the control (adjuvant
only) group (Fig. 1B).
In Trial 2, sheep began to excrete nematode eggs from 14 to 16
days after challenge (Fig. 1C). At peak egg shedding (day 86) mean
FWECs in the extant immunized group (Group 3) were 251 ± 75
EPG, whereas in the control group (Group 4) they were 908 ± 158
EPG, representing a 73% reduction in mean FWEC. Mean cumulative
FWECs in Trial 2 were 4998 (±) 2233 EPG in Group 1 (immunized)
and 4127 (±) 803 EPG in Group 2 (adjuvant only, Fig. 1D). Using
Cook’s distance criterion, sheep 675 J was  regarded as a “highly
inﬂuential” case (D = 0.3129 based on a LMM  model) on the high
mean FWECs and associated SEM for Group 1. For Groups 3 and
4, which were necropsied 4 weeks after Groups 1 and 2, mean
cumulative FWECs were 7005 (±) 681 EPG in Group 3 (immu-
nized) and 16,727 (±) 2699 EPG in Group 4 (control, adjuvant only),
representing an overall mean FWEC reduction of 58% in the immu-
nized versus the control group (Fig. 1D). GAMM analysis indicated
a statistically-signiﬁcant effect of immunization (data from Groups
1 and 3 combined versus Groups 2 and 4 combined) on mean FWEC
over the course of the experiment (P = 0.024).
3.2. Abomasal nematode burdens
3.2.1. Trial 1
On average, immunized sheep (Group 1) harbored 55% fewer T.
circumcincta (total of adults and juveniles) at necropsy than control,
adjuvant only (Group 2) sheep (P = 0.011, Fig. 2A). Group 1 sheep
had statistically-signiﬁcantly lower mean adult nematode burdens
than sheep in Group 2 (75% reduction, P = 0.007, Fig. 2A). Compari-
son of mean juvenile nematode burdens in the abomasum indicated
no signiﬁcant differences between the groups (Fig. 2A). No sig-
niﬁcant differences were observed in the mean length of worms
recovered from the different groups.
3.2.2. Trial 2
3.2.2.1. Groups 1 and 2 (post mortem at day 84). The mean total
abomasal nematode burdens (adults and juveniles) in immunized
sheep were not statistically signiﬁcantly different to those from the
control, adjuvant only group (mean total nematode burdens ± SEM:
Group 1; 6843 ± 1144, Group 2; 6250 ± 966).
3.2.2.2. Groups 3 and 4 (post mortem at day 112). On average, immu-
nised sheep (Group 3) harbored 57% fewer T. circumcincta total
nematodes at necropsy than did the control, adjuvant only (Group
4) recipients (P = 0.020, Fig. 2B). In both Groups 3 and 4, adult worms
comprised 99% of the total nematode burden.
3.3. Measurement of serum antibody responses to T. circumcincta
antigens
In both trials, 7–14 days after tertiary immunization, serum
IgG levels against all recombinant proteins reached peak levels,
then declined slowly [Supplementary Information (SI) Figs. S1, S2].
Serum IgA levels peaked after secondary immunization and, for all
recombinants with the exception of Tci-MIF-1, remained relatively
constant until the end of the experiment. Immunized sheep pro-
duced serum IgG, prior to parasite challenge, which bound native
L4 ES components (SI, Fig. S3): IgG bound to parasite components,
in L4 ES, somatic extracts of L4 and adult T. circumcincta, of the
expected size range for Tci-CF-1 (23.9 kDa), Tci-APY-1 (38.6 kDa)
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Fig. 1. Effects of immunization of sheep with recombinant antigens derived from Teladorsagia circumcincta on fecal worm egg counts (FWEC) after challenge infection. Panels
A  and C: FWECs of sheep challenged with 2000 T. circumcincta three times per week for 4 weeks following immunization with an 8-protein cocktail in the context of Quil
A  (dashed line) or with Quil A only (solid line). Each data point represents the arithmetic mean FWEC ± SEM. Panel A represents data from Trial 1; Panel C represents data
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Trom  Trial 2. Panels B and D show cumulative FWECs, for each animal in each grou
-protein cocktail; “Con” represents those administered with Quil A adjuvant only
4  days, whereas for Groups 3 and 4 cumulative FWEC is calculated over 112 days. 
nd Tci-MEP-1 (55.6 kDa) (Fig. 3A). Serum IgA also bound parasite
omponents of the expected size range for vaccine components Tci-
F-1, Tci-APY-1 and Tci-MEP-1 (Fig. 3B). In addition, IgA bound
 parasite component of ca. 43 kDa in L3 somatic extract. From
4 days after initiation of challenge, control, adjuvant only recip-
ents generated serum IgG that bound recombinant Tci-MEP-1
nd Tci-APY-1 but no other recombinants (SI Fig. S4). Antigen-
peciﬁc serum IgA which bound to the recombinant proteins was
ot observed in these control sheep.
.4. Measurement of mucus antibody responses to recombinant
ntigens
Mean antigen-speciﬁc IgG levels in abomasal mucus of the
mmunized sheep were signiﬁcantly higher than in the control
heep for each protein (SI, Figs. S5A and S6A). In Trial 1, mean Tci-
PY-1-, Tci-MEP-1-, and Tci-CF-1-speciﬁc IgG levels were higher
han for the other recombinants (P < 0.0001). In Trial 2, mean Tci-
EP-1-speciﬁc IgG levels were signiﬁcantly higher than for the
emaining antigens (Day 84 necropsy) while mean Tci-MEP-1- and
ci-APY-1-speciﬁc IgG levels were signiﬁcantly higher at the Dayrial 1 (Panel B) and Trial 2 (Panel D). “Imm” represents sheep immunized with the
 that, in panel D, for Groups 1 and 2 in Trial 2, cumulative FWEC is calculated over
outlier” animal in Group 1 of Trial 2, sheep number 675 J, is indicated.
112 necropsy. Mucus Tci-APY-1- and Tci-MEP-1-speciﬁc IgA levels
were signiﬁcantly higher than those directed against the other six
antigens (SI, Figs. S5B and S6B).
4. Discussion
Here, we  demonstrate that immunization of sheep with a cock-
tail of eight recombinant proteins induces levels of protection
against T. circumcincta which are higher than those observed in
any other system using a recombinant vaccine against a para-
sitic nematode in the deﬁnitive ruminant host. Previous attempts
to immunise mammalian hosts against parasitic nematodes have
used:
(i) Irradiated larvae. In the case of the bovine lungworm, Dicty-
ocaulus viviparus [36] and the dog hookworm, A. caninum [37]
these have given high levels of protection and yielded commer-
cial products. This approach was  not successful for a number
of other nematodes including T. circumcincta [38].
(ii) Native extracts. There are numerous examples of the use
of extracts of dead parasites, or sub-fractions thereof, to
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Fig. 2. Effects of immunization of sheep with recombinant antigens derived from
Teladorsagia circumcincta on abomasal nematode burden after challenge infection.
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Fig. 3. Immunoblots to investigate serum IgG (Panel A) and IgA (Panel B) binding
to  components of somatic extracts and excretory/secretory products of Teladorsagia
circumcincta.  Lanes 1 and 5 contain L3 somatic extract, lanes 2 and 6 contain L4
somatic extract, lanes 3 and 7 contain L4 ES material and lanes 4 and 8 contain adult
somatic extract. Blots were incubated with sera pooled from 7 immunized sheep
(Lanes 1–4, sheep from Group 3, Trial 2) or non-immunized sheep (Lanes 5–8, sheep
from Group 4, Trial 2). Sera had been collected from the animals on the date of theasum ± SEM (n = 7). Panel A depicts the nematode burdens in Trial 1, panel B the
dult nematode burden in Group 3 (immunized) or Group 4 (control, adjuvant only)
f  Trial 2.
immunise hosts against parasitic nematodes [39]. In T. circum-
cincta,  when detergent extracts of L3 were used as immunogen,
anti-parasite responses were variable, but parasite burdens
were signiﬁcantly reduced (by up to 72%) and FWECs reduced
by more than 70% [40,41]. Other attempts to protect sheep
against T. circumcincta using native antigen preparations,
for example lectin-binding integral membrane glycoproteins
[42,43], were unsuccessful.
iii) Recombinant subunit vaccines. A number of studies have
reported difﬁculties in stimulating protective immunity with
recombinant antigens [44–46]. For example, the N-type single
domain ASPs, Oo-ASP-1 and Oo-ASP-2, are principal compo-
nents of an ASP-enriched native extract of Ostertagia ostertagi,
which has been used with success to immunize cattle against
challenge [45,47,48]. However, immunization with a recombi-
nant version of Oo-ASP-1 failed to induce protective immunity
[44]. Other protection trials using single recombinant proteins
have also failed: in O. ostertagi, for example, the astacin-like
metalloproteinase MET-1, which shares 50% amino acid iden-
tity with Tci-MEP-1, failed to stimulate protection [49]. In
addition, a recombinant version of the Necator americanus
orthologue of Tci-SAA-1 (Na-SAA-1) did not induce signiﬁcant
protection against L3 challenge in a hamster model [50].
In contrast, our multi-component vaccine reduced FWECs and
dult parasite burdens by >70% in Trial 1. It is not essential for a
accine against ruminant parasitic nematodes to be 100% effective,
nd “substantial beneﬁts” can be gained by using a vaccine that is
0% effective in 80% of the ﬂock [51]. It has also been postulated
hat a vaccine which could reduce egg output by 60% in O. ostertagi
nfected calves during the ﬁrst 2 months on pasture could controlthird immunization immediately prior to the initiation of trickle infection. Images
shown are from Trial 2, Trial 1 sera reacted in a highly similar fashion. * represents
molecular mass (kDa).
bovine ostertagiosis by reducing peak pasture contamination while
also allowing natural immunity to develop [47,48].
The serological analyses presented here (Figs. S1–S6) demon-
strate that co-administration of immunomodulatory molecules
with other vaccine antigens did not prevent high antigen-speciﬁc
antibody levels developing. Although the recombinant antigens
elicited high serum antibody levels following immunization in both
Trials, there was  no antigen-speciﬁc anamnestic response following
parasite challenge. Thus, if the observed protection is antibody-
based, high antibody levels produced by vaccination could protect
young lambs when they are most susceptible to detrimental effects
of T. circumcincta infection [52] but, because the vaccine does not
produce sterile immunity, naturally-acquired immunity (which
develops as the lambs mature [11]) would be allowed to develop
through exposure to the limited numbers of L3 from pasture.
Overall, both trials produced comparable effects, although the
timing differed. In Trial 1, when post mortems were conducted at
day 84, vaccinated sheep contained 75% fewer adult nematodes
than non-vaccinated sheep. In Trial 2 however, the effects of the
vaccine on both FWEC and nematode burden were not obvious
by day 84, with the differences between the vaccinated animals
and the control animals becoming clearer later in the experiment.
This observation may  have been related to the ages of the animals
involved in each trial–lambs in Trial 2 were ∼30 days younger than
those in Trial 1 and may  have been less able to control the infectious
dose [11,19].
Further studies with the recombinant vaccine will focus on
a reductionist approach to determine the most simple, effective
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here infection with T. circumcincta has the highest economical and
elfare impacts [52].
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